• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Alpha Tau Medical Ltd.

    1/12/26 7:35:13 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care
    Get the next $DRTS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001968095
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Alpha Tau Medical Ltd.
    SEC File Number
    001-41316
    Address of Issuer
    KIRYAT HAMADA 5
    JERUSALEM
    ISRAEL
    9777605
    Phone
    972-3-577-4115
    Name of Person for Whose Account the Securities are To Be Sold
    Levy Raphi
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Ordinary
    Oppenheimer & Co Inc.
    Broad 85 St.
    New York � NY � 10004
    25000160250.007038057001/09/2026
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Ordinary08/08/2021RSUIssuerCheckbox not checked7000008/08/2021N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Levy Raphi
    KIRYAT HAMADA 5
    JERUSALEM � L3 � 9777605
    Ordinary01/08/202620000121650.00

    144: Remarks and Signature

    Remarks
    Under 10b5 sale plan signed on 03-17-25
    Date of Notice
    01/09/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    03/17/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Levy Raphi

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $DRTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRTS

    DatePrice TargetRatingAnalyst
    12/15/2023$8.00Buy
    Citigroup
    4/24/2023$9.00Buy
    H.C. Wainwright
    4/14/2022$20.00Overweight
    Cantor Fitzgerald
    4/8/2022$19.00Overweight
    Piper Sandler
    4/4/2022$21.00Buy
    Citigroup
    More analyst ratings

    $DRTS
    SEC Filings

    View All

    SEC Form 144 filed by Alpha Tau Medical Ltd.

    144 - Alpha Tau Medical Ltd. (0001871321) (Subject)

    1/12/26 7:35:13 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

    1/6/26 9:02:01 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

    1/5/26 9:02:01 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

    - Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treatments, as well as potential anti-inflammatory effect - - Alpha DaRT currently being studied together with first-line chemotherapy in U.S. multi-center pilot trial for newly diagnosed pancreatic cancer - JERUSALEM, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced the release of final results from its first-i

    1/6/26 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

    - Initial module submission marks an important milestone in the pre-market approval process -  - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted - - Module submitted in parallel to execution of ReSTART pivotal study (Recurrent SCC Treatment with Alpha DaRT Radiation Therapy), which is expected to complete recruiting patients in Q1 2026 - JERUSALEM, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau", or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced the submission of the first module

    1/5/26 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

    JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 11:15am PT / 2:15pm ET, in San Francisco, CA, and will host institutional investor meetings at the event. Event:J.P. Morgan 2026 Healthcare ConferenceFormat:Presentation and 1-on-1 MeetingsDate:January 15, 2026Time:11:15AM PT – 11:55AM PTLocation:Westin St. Francis, San Francisco, CA Webcast: Link will be posted on the

    12/18/25 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Alpha Tau with a new price target

    Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00

    12/15/23 8:07:49 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Alpha Tau with a new price target

    H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00

    4/24/23 7:44:43 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on Alpha Tau with a new price target

    Cantor Fitzgerald initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $20.00

    4/14/22 7:17:36 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

    JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., ("Oramed"), has been appointed to the Company's Board of Directors ("Board"). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed. "Nadav is a fantastic addition to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "He has spent many years in a position much like ours, at the helm of a public compa

    5/12/25 4:01:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

    - Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t

    3/12/25 4:02:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

    JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors ("Board"). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity. "I am delighted to welcome Maya to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "Maya brings a wealth of experience and a keen under

    12/17/24 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care